Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Tofts

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Orphanet Journal of Rare Diseases|January 22, 2021
Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasiaPenelope J Ireland, Ravi Savarirayan, Tash Pocovi, et al.
Children (Basel, Switzerland)|March 17, 2019
Longitudinal Fibular Deficiency: A Cross-Sectional Study Comparing Lower Limb Function of Children and Young People with That of Unaffected PeersJoshua W Pate, Mark J Hancock, Louise Tofts, et al.
Children (Basel, Switzerland)|July 27, 2024
Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in AustraliaLouise Tofts, Penny Ireland, Tracy Tate, et al.
Disability and Rehabilitation|December 17, 2020
Physical performance of children with longitudinal fibular deficiency (fibular hemimelia)Eleanor J Morris, Louise Tofts, Margaret Patterson, et al.
BMJ Open|October 30, 2024
Breadth and visibility of children's lower limb chronic musculoskeletal pain: a scoping reviewEmre Ilhan, Luke Davies, Verity Pacey, et al.
Bone|February 5, 2021
Lifetime impact of achondroplasia: Current evidence and perspectives on the natural historyJulie Hoover-Fong, Moira S Cheung, Virginia Fano, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Lancet (London, England)|September 6, 2020
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trialRavi Savarirayan, Louise Tofts, Melita Irving, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2021
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension studyRavi Savarirayan, Louise Tofts, Melita Irving, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 15, 2022
Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational studyRavi Savarirayan, Melita Irving, Paul Harmatz, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Orphanet Journal of Rare Diseases|January 22, 2021
Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasiaPenelope J Ireland, Ravi Savarirayan, Tash Pocovi, et al.
Children (Basel, Switzerland)|March 17, 2019
Longitudinal Fibular Deficiency: A Cross-Sectional Study Comparing Lower Limb Function of Children and Young People with That of Unaffected PeersJoshua W Pate, Mark J Hancock, Louise Tofts, et al.
Children (Basel, Switzerland)|July 27, 2024
Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in AustraliaLouise Tofts, Penny Ireland, Tracy Tate, et al.
Disability and Rehabilitation|December 17, 2020
Physical performance of children with longitudinal fibular deficiency (fibular hemimelia)Eleanor J Morris, Louise Tofts, Margaret Patterson, et al.
BMJ Open|October 30, 2024
Breadth and visibility of children's lower limb chronic musculoskeletal pain: a scoping reviewEmre Ilhan, Luke Davies, Verity Pacey, et al.
Bone|February 5, 2021
Lifetime impact of achondroplasia: Current evidence and perspectives on the natural historyJulie Hoover-Fong, Moira S Cheung, Virginia Fano, et al.
The Lancet. Child & Adolescent Health|November 20, 2023
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trialRavi Savarirayan, William R Wilcox, Paul Harmatz, et al.
Lancet (London, England)|September 6, 2020
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trialRavi Savarirayan, Louise Tofts, Melita Irving, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2021
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension studyRavi Savarirayan, Louise Tofts, Melita Irving, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 15, 2022
Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational studyRavi Savarirayan, Melita Irving, Paul Harmatz, et al.
Pageof 3